At Week 12, secukinumab had also reduced the number of lesional CD11c-positive dendritic cells and T cells similar to what has been proposed to coincide with more final disease resolution during treatment with other targeted therapies for psoriasis 3. Here, ITGAX is linked to psoriasis.